Document Detail

Effect of topical application of terbinafine on fungal keratitis.
MedLine Citation:
PMID:  19781365     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Fungal keratitis is a rare but serious corneal disease that may result in loss of vision. The poor prognosis might be due to limited treatment option. This study aimed to evaluate the clinical efficacy of 0.25% terbinafine eye drops comparing with 5% natamycin suspension on fungal keratitis. METHODS: A retrospective clinical trial was performed on 90 patients presenting with direct smear and/or culture positive fungal keratitis at Beijing Tongren Hospital, Beijing, China from January 2006 to May 2008. Corneal ulcers were categorized as mild or severe. Forty-five patients were treated with topical terbinafine and the next 45 cases received topical natamycin hourly. RESULTS: Filamentous fungi were found in corneal scrapings among all 90 cases. Fungal cultures were positive in 64 patients (71%). Species of Fusarium and Aspergillus were the principal isolates. Forty (89%) patients showed favorable response to terbinafine, while forty-two (93%) patients exhibited favorable response to natamycin (P > 0.05). The mean course of treatment was significantly showed in the terbinafine treatment group than natamycin group ((26.5 +/- 11.2) days versus (19.3 +/- 6.4) days; P < 0.05). In terbinafine group, twenty patients with ulcers smaller than 4 mm had favorable outcome, while 20 of 25 patients with ulcers more than 4 mm in diameter had favorable response (P < 0.05). Twenty-seven patients with depth of infiltration less than half of stroma thickness had favorable response to terbinafine, while 13 of 18 patients with depth of infiltration more than half of stroma responded to terbinafine. This difference was statistically significant (P < 0.05). CONCLUSIONS: Our findings suggest that topical terbinafine is an effective antifungal drug for the management of filamentous mycotic keratitis, particularly in cases with smaller and shallower ulcers. Its mean duration of treatment was longer than natamycin.
Qing-feng Liang; Xiu-ying Jin; Xiang-lan Wang; Xu-guang Sun
Related Documents :
9561595 - Phase ii trial in china of a new, rapidly-acting and effective oral antimalarial, cgp 5...
16190505 - Herpes zoster and postherpetic neuralgia: prevention and management.
3890575 - A clinical trial of mefloquine in the treatment of plasmodium vivax malaria.
17712755 - The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimen...
24310235 - Contralateral lateral rectus muscle recession in patients with duane retraction syndrom...
17218915 - Long-term outcomes of vitrectomy with or without arteriovenous sheathotomy in branch re...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chinese medical journal     Volume:  122     ISSN:  0366-6999     ISO Abbreviation:  Chin. Med. J.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-09-28     Completed Date:  2010-02-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513795     Medline TA:  Chin Med J (Engl)     Country:  China    
Other Details:
Languages:  eng     Pagination:  1884-8     Citation Subset:  IM    
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antifungal Agents / therapeutic use*
Aspergillus / isolation & purification,  physiology
Fusarium / isolation & purification,  physiology
Keratitis / drug therapy*,  microbiology*
Naphthalenes / therapeutic use*
Natamycin / therapeutic use
Retrospective Studies
Treatment Outcome
Reg. No./Substance:
0/Antifungal Agents; 0/Naphthalenes; 7681-93-8/Natamycin; 91161-71-6/terbinafine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical features and follow-up of Chinese patients with symptomatic hypogammaglobulinemia in infanc...
Next Document:  Modern use of Chinese herbal formulae from Shang-Han Lun.